“There is a growing prevalence of early-onset type 2 diabetes and more people are expected to develop type 2 diabetes at lower body weights, especially in low- and middle-income countries,” says Naveed Sattar. In this Day 4 edition of the EASD e-Learning Newsflash, he reports on the origins and implications for the clinic as discussed in the Lancet Symposium he chaired. Vanita Aroda presents findings from the CATALYST trial, which tested mifepristone in people with hypercortisolism and difficult-to-control type 2 diabetes. Francesco Giorgino outlines the potential of a novel monoclonal antibody that targets the activin pathway in skeletal muscle and in adipose tissue –– as presented in a late–breaking symposium on the BELIEVE trial. This new approach could help prevent muscle loss often seen with weight-loss therapies. Giorgino furthermore comments on emerging data on a GIP antagonist coupled with a GLP-1 receptor agonist from the MariTide phase 2 study, looking forward to new releases of incretin-based clinical trials at the upcoming EASD Annual meeting. 

Interviewees: 

• Prof. Naveed Sattar, University of Glasgow  
• Dr Vanita Aroda, Harvard Medical School  
• Prof. Francesco Giorgino, University of Bari Aldo Moro  

Staff: 

• Interviewer: Dr Albert Brugger
• Videographer: Christian Fichtner, Bsc